Costs support infliximab as first-line salvage therapy.

The high costs of infliximab in the initial management of steroid-refractory acute severe ulcerative colitis (ASUC) are largely offset with the savings from avoiding hospitalisation and procedure-related costs. And the equation should only improve in favour of anti-TNF therapy with the growing uptake of biosimilars, a Victorian research team said. Their study of 118 patients ...

Already a member?

Login to keep reading.

© 2021 the limbic